...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Biotech Showcase

Also, both Resverlogix and Zenith are listed as presenting companies at BIO CEO Investor Conference in New York February 11-12, 2019

Share
New Message
Please login to post a reply